For Q1 FY2026 ending December, revenue was JPY 11,256 million (up 69.4% YoY), operating income turned positive to JPY 3,244 million, and quarterly profit was positive at JPY 1,793 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexelapharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4565-20260501-02.pdf","jir_short_summary":"For Q1 FY2026 ending December, revenue was JPY 11,256 million (up 69.4% YoY), operating income turned positive to JPY 3,244 million, and quarterly profit was positive at JPY 1,793 million.","jir_summary":"### Performance Overview\nIn Q1 FY2026 ending December, revenue reached JPY 11,256 million (up 69.4% YoY), and operating income turned positive to JPY 3,244 million. Quarterly profit was positive at JPY 1,793 million, and the equity ratio attributable to owners of the parent rose to 47.8%. The main drivers of revenue growth were strong sales of Pivlats\u00ae and Cubivic\u00ae, along with a significant increase in milestone income. Research and development expenses were JPY 3,028 million, down compared to the same period last year, with ongoing cost reduction initiatives.\n\n### Outlook and Business Strategy\nFull-year earnings guidance for FY2026 ending December forecasts revenue between JPY 33,800 million and JPY 48,800 million, with operating income ranging from JPY 700 million to JPY 15,700 million. Revenue from Pivlats\u00ae and Cubivic\u00ae is expected to be between JPY 13.8 billion and JPY 14.2 billion, and JPY 5 billion to JPY 6 billion, respectively. New partnerships and increased milestone income are expected to contribute to performance. We are advancing new drug development leveraging the drug discovery platform technology NxWave\u2122, as well as late-stage clinical development in the Asia-Pacific region, aiming for strategic growth.","jir_financial_highlights":"Revenue: JPY 11,256 million (Up 69.4% YoY)\nOperating Income: JPY 3,244 million (Turned positive from an operating loss of JPY 2,193 million in the previous year)\nQuarterly Profit: JPY 1,793 million (Turned positive from a loss of JPY 760 million in the previous year)\nEquity Ratio Attributable to Owners of Parent: 47.8% (Up 2.5 points compared to the end of the previous period)\nNumber of Shares Outstanding (Common Shares): 90,496,735 shares (No change from previous period end)\nCore Operating Profit\/Loss: JPY 5,495 million (Turned positive from a loss of JPY 625 million in the previous year)","jir_category":"","jir_hashtags":"#Nexelapharma, #FinancialSummary, #Biopharmaceuticals","jir_key_figures":"Revenue: JPY 11,256 million (up 69.4% YoY)\nOperating Income: JPY 3,244 million (turning positive from a loss of JPY 2,193 million in previous year)\nQuarterly Profit: JPY 1,793 million (turning positive from a loss of JPY 760 million in previous year)","jir_meta_title":"[Nexelapharma] FY2026 Q1 Financial Results | Revenue JPY 11.2 Billion (+69.4% YoY)","jir_meta_description":"Financial Summary for Nexelapharma Co., Ltd. Q1 FY2026. Revenue was JPY 11,256 million (up 69.4% YoY), and operating income turned positive to JPY 3,244 million. Future earnings outlook also included.","jir_og_title":"[Nexelapharma] FY2026 Q1 Financial Results | Revenue JPY 11.2 Billion (+69.4%)","jir_og_description":"Achieved revenue growth and operating income turnaround in Q1 FY2026. Strong sales of Pivlats\u00ae and Cubivic\u00ae driving performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trend in Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (JPY million)\\\",\\\"data\\\":[6644,11256],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trend in Operating Income\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (JPY million)\\\",\\\"data\\\":[-2193,3244],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trend in Quarterly Profit\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit (JPY million)\\\",\\\"data\\\":[-760,1793],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Composition for Q1 FY2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pivlats\u00ae\\\",\\\"Cubivic\u00ae\\\",\\\"Respiratory Diseases\\\",\\\"R&D and Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[2921,1408,351,4576],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]}}\"}, {\"jir_chart_id\": \"core_operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"YoY Trend in Core Operating Profit\/Loss\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2025\\\",\\\"Q1 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\/Loss (JPY million)\\\",\\\"data\\\":[-625,5495],\\\"backgroundColor\\\":\\\"#edc949\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-44766","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n